Neoplasms

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Rare Diseases

Carcinoma

Stomach Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Disease Progression

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Stomach Diseases

Stomach Cancer

All Drugs and Chemicals

Antineoplastic Agents

Hematinics

Coagulants

Antibodies

Antibodies, Monoclonal

Immune Checkpoint Inhibitors

Nivolumab

Immunoglobulins

Liver Extracts

Gelatin Sponge, Absorbable

Ethiodized Oil

Tirapazamine

Antineoplastic Agents, Immunological

PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression.

TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.

PD-1 inhibitor (Nivolumab 360 mg Q3W IV) starts at day 1, and continues until progression.

TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.

Nivolumab Injectable Product

Trans-arterial tirapazamine embolization

Ray Lee, MD. PhD

Chiwei Lu, PhD.

Miranda Duron

Nadine Abi-Jaoudeh, MD

Melissa Yarbrough, RN

Barbara Dion

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

The goal of the study is to investigate whether tumor necrosis induced by Trans-arterial Tirapazamine Embolization (TATE) treatment can boost anti-tumor immunity and enhance the therapeutic efficacy of immune checkpoint inhibitor. Patients with advanced liver cancers (primary HCC or metastatic gastric cancer) who have progressed on a prior immune checkpoint inhibitor will be enrolled in the study. Liver lesions will be treated with up to 4 TATE treatments for optimal debulking, which also serve as a vaccination process toward tumor. Lesion not treated with TATE will be used for monitoring the response toward a PD-1 inhibitor (Nivolumab) for abscopal effect. If a patient subsequently develops an "escape" to the PD-1 inhibitor, patient can have another 2 TATE treatments of the escaped tumor lesion. Dosing of the PD-1 inhibitor is per standard FDA-approved dosing schedule and continues until progressive disease. The efficacy will be assessed by the response rate (RR) using RECIST.

One arm for advanced HCC, and one for second line metastatic gastro-esophageal cancer . All enrolled patients will receive the same treatment with TATE and a PD-1 inhibitor (nivolumab) until disease progression

Combination of TATE and PD-1 Inhibitor in Liver Cancer

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

From the date of image-demonstrated response to the date of progression

From randomization to disease progression or death

Teclison Ltd.

Skin and Connective Tissue Diseases

Sarcoma

Recurrence

Osteosarcoma

Sarcoma, Ewing

Rhabdomyosarcoma

Sarcoma, Synovial

Neoplasms, Connective and Soft Tissue

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Myosarcoma

Soft Tissue Sarcoma

Ewing Sarcoma

Synovial Sarcoma

Embryonal Sarcoma

Pembrolizumab

autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody pembrolizumab

autologous HER2 CAR T cells infused in combination with lymphodepletion chemotherapy and the PD-1 antibody nivolumab

There are 2 dose levels:

Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.

T cells or CAR T cells

2 mg/kg/dose (max 200 mg/dose) every 3 weeks

Pembrolizumab Injectable Product

3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks

Meenakshi Hegde, MD

Shoba Navai, MD

Nabil Ahmed, MD

The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or nivolumab), to learn what the side effects are, and to see whether this therapy might help patients with sarcoma.

Another goal of this study is to study the bacteria found in the stool of patients with sarcoma who are being treated with HER2 CAR T cells and immune checkpoint inhibitor drugs to see if the types of bacteria influence how well the treatment works.

The investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to see if they can put a new gene in these cells that will let the T cells recognize and kill sarcoma cells. The new gene that the investigators will put in makes an antibody specific for HER2 (Human Epidermal Growth Factor Receptor 2) that binds to sarcoma cells. In addition, it contains CD28, which stimulated T cells and make them last longer. After this new gene is put into the T cell, the T cell becomes known as a chimeric antigen receptor T cell or CAR T cell.

In another clinical study using these CAR T cells targeting HER2 as well as other studies using CAR T cells, investigators found that giving chemotherapy before the T cell infusion can improve the effect the T cells can have. Giving chemotherapy before a T cell infusion is called lymphodepletion since the chemotherapy is specifically chosen to decrease the number of lymphocytes in the body. Decreasing the number of the patient's lymphocytes first should allow the infused T cells to expand in the body, and potentially kill cancer cells more effectively.

The chemotherapy used for lymphodepletion is a combination of cyclophosphamide and fludarabine.

After the patient receives the lymphodepletion chemotherapy and CAR T cells during treatment on the study, they will receive an antibody drug called an immune checkpoint inhibitor, pembrolizumab or nivolumab. Immune checkpoint inhibitors are drugs that remove the brakes on the immune system to allow it to act against cancer.

Patients will first be asked to give blood to make the HER2 CAR T cells. These cells are grown and frozen for the patient. To get the HER2 antibody (and the CD28zeta) to attach to the surface of the T-cell, investigators insert the antibody gene into the T-cell. This is done with a virus called a retrovirus that has been made for this study and will carry the antibody gene into the T cell. This virus also helps the investigators find the T cells in the patient's blood after they are injected. Because the patients in this study receive cells with a new gene in them, they will be followed for a total of 15 years to see if there are any long-term side effects of gene transfer.

Patients will receive cyclophosphamide for 2 days followed by fludarabine for 5 days before receiving the HER2 CAR T cells. These chemotherapies may be given in the clinic or hospital.

The fludarabine, cyclophosphamide, and HER2 CAR T cells will be given intravenously (through a needle inserted into a vein or port-a-cath or another type of central venous line).

Before the patient receives the injection of HER2 CAR T cells, they may be given a dose of Benadryl (Diphenhydramine) and Tylenol (Acetaminophen). The injection of T cells will take between 1 and 10 minutes. Patients will be monitored in the clinic or hospital after the injection for up to 4 hours. The treatment will be given by the Center for Cell and Gene Therapy at Texas Children's Hospital. Patients will be follow ed in the clinic after the T-cell injection and also by disease evaluations from their primary doctor.

One week after the patient receives the HER2 CAR T cells,they will begin receiving an immune checkpoint inhibitor pembrolizumab every three weeks or nivolumab every two weeks . If the patient experiences any immune side effects from treatment with the HER2 CAR T cells, treatment with pembrolizumab (or nivolumab) will be delayed until they have recovered from those side effects. Pembrolizumab (or nivolumab) is given intravenously and at Texas Children's Hospital.

Medical tests before treatment

Before being treated, patients will receive a series of standard medical tests:

* Physical exam
* Blood tests to measure blood cells, inflammation, kidney and liver function
* Heart function test (Echocardiogram)
* Measurements of the tumor by imaging studies that were used before to follow the tumor such as Computer Tomogram (CT), Magnetic Resonance Imaging (MRI), or Positron Emission Tomography (PET/CT).
* If the tumor has spread to the patient's bone marrow, bone marrow aspiration and biopsy may also be used to measure the tumor in addition.
* Chest X-Ray to assess the lungs

Medical tests during and after treatment

Patients will receive standard medical tests when they are getting the infusions and after:

* Physical exams
* Blood tests to measure blood cells, inflammation, kidney, and liver function
* Heart function test (Echocardiogram) at 6 weeks after the infusion
* Measurements of the tumor by imaging studies 6 weeks after the infusion
* If the tumor was previously detected in the bone marrow, bone marrow studies (bone marrow aspiration and biopsy) will be performed 6 weeks after the infusion to follow the tumor.

To learn more about the way the HER2 CAR T cells are working and how long they last in the body, an extra amount of blood, based on the patient's weight, up to a maximum of 60 ml (12 teaspoons) of blood will be taken on the day of the T-cell infusion, before and at the end of the T-cell infusion, 1, 2, 4 and 6 weeks after the T-cell infusion and every 3 months for 1 year, every 6 months for 4 years, then yearly for a total of 15 years. One additional blood sample might be drawn 3 to 4 days after the T-cell infusion; this is optional. If the patient develops fever or other inflammation following CAR T cell injection, additional blood samples may be collected daily until the inflammation has resolved. For children, the total amount of blood drawn will not be more than 3 ml (less than 1 teaspoon) per 1 kg of body weight on any one day. This volume is considered safe but may be decreased if the patient is anemic.

During the time points listed above, if the T cells are found in the patient's blood at a certain amount an extra 5 ml of blood may need to be collected for additional testing.

To perform the bacteria studies on the patient's stool, the patient with provide a stool sample during chemotherapy, after HER2 CAR T cell infusion, and after starting pembrolizumab (or nivolumab) treatment, and at optional additional timepoints for up to 6 months after treatment stops.

If the patient received the prescribed treatment (lymphodepletion chemotherapy, HER2 CAR T cells, and two doses of pembrolizumab or nivolumab) and tolerated the treatment well, they can receive additional doses of the T cells at 6 to 12 weeks intervals and continue on treatment with pembrolizumab or nivolumab if they wish for up to 12 weeks after the last T cell infusion. After each T-cell infusion, the patient will be monitored as described above.

If the patient has a tumor biopsy performed any time while they are on study, a sample of this will be used for research purposes (if a sample can be obtained).

If the patient develops a second abnormal growth, significant blood or nervous system disorder during the trial, a biopsy sample of the tissue will be tested (if a sample can be obtained).

Patients will receive supportive care for acute or chronic toxicity, including blood components or antibiotics, and other intervention as appropriate.

Patients will be non-randomly assigned to one of two arms, Arm A or Arm B. Dose de-escalation will occur independently in each arm.

Arm A treatment will consist of autologous HER2 CAR T cells infused in combination with lymphodepletion and the PD-1 antibody pembrolizumab. Accrual will start at Dose Level 1. In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.

Arm B treatment will consist of autologous HER2 CAR T cells infused in combination with lymphodepletion and the PD-1 antibody nivolumab. Accrual will start at Dose Level 1. In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Any grade 5 event, Grade 3 and 4 cytokine release syndrome (CRS) or neurological toxicities that fail to return to grade 2 within 5 days of T cell infusion , and all other grade 3 or 4 toxicities (including allergic reactions to T cell infusions) that fail to return to grade 2 within 72 hours.

In the event that the combination treatment potentiates expected, severe toxicities attributable to PD-1 antibody, investigators will employ an additional stopping rule which will be applied to each arm separately. If (1) two within the initial six patients treated or (2) greater than 33% of all patients thereafter develop greater than or equal to grade 3 non-hematologic, non-dermatologic toxicity attributable to PD-1 antibody but not attributable to HER2 CAR T cells during the DLT window, investigators will pause enrollment to that study arm.

Toxicity will be evaluated according to the CTCAE v5.0 except for CRS and neurotoxicity.

Subjects who receive at least one dose of HER2 CAR T cells and two doses of PD-1 antibody are evaluable.

Response in patients with disease measurable by imaging will be determined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Center for Cell and Gene Therapy, Baylor College of Medicine

The Faris Foundation USA

Stand Up To Cancer

Triumph Over Kid Cancer Foundation

St. Baldrick's Foundation

National Cancer Institute (NCI)

Baylor College of Medicine

Associate Professor

Gland and Hormone Related Diseases

Pancreatic Neoplasms

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill

Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion

Allosteric inhibitor to human CXCR1 and CXCR2 receptor

SX-682

humanized monoclonal antibody to program cell death receptor 1 (PD1)

Chris LeFeber

Richard Dunne

Richard Dunne, MD

The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

In this study the investigator would like to better understand the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression. In addition, the investigator would like to measure the SX-682 pharmacokinetic data in humans. The investigator would also like to assess the immunophenotypic and stromal changes to the tumor microenvironment after treatment.

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Maximum tolerable dose is defined by less than or equal to 30% dose limiting toxicity (DLT) event rate within a given dose combination,

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination of TATE and PD-1 Inhibitor in Liver Cancer	NCT03259867	Hepatocellular ... Gastric Cancer	Nivolumab Injec... Trans-arterial ...	18 Years - 80 Years	Teclison Ltd.
Combination of TATE and PD-1 Inhibitor in Liver Cancer	NCT03259867	Hepatocellular ... Gastric Cancer	Nivolumab Injec... Trans-arterial ...	18 Years - 80 Years	Teclison Ltd.
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma	NCT04995003	Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate...	T cells or CAR ... Pembrolizumab I... Nivolumab Injec...	1 Year - 25 Years	Baylor College of Medicine
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	NCT04477343	Pancreatic Duct... Pancreatic Canc...	SX-682 Nivolumab Injec...	18 Years -	University of Rochester
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma	NCT04995003	Sarcoma HER-2 Protein O... Osteosarcoma Rhabdomyosarcom... Ewing Sarcoma Synovial Sarcom... Soft Tissue Sar... Undifferentiate...	T cells or CAR ... Pembrolizumab I... Nivolumab Injec...	1 Year - 25 Years	Baylor College of Medicine
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	NCT04477343	Pancreatic Duct... Pancreatic Canc...	SX-682 Nivolumab Injec...	18 Years -	University of Rochester

Spots Global Cancer Trial Database for nivolumab injectable product